User menu

The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.

Bibliographic reference Van Laere, Koen ; Everaert, Ludwig ; Annemans, Lieven ; Gonce, Michel ; Vandenberghe, Wim ; et. al. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, no. 7, p. 1367-1376 (2008)
Permanent URL
  1. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266–72.
  2. Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002;29:1623–9.
  3. Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005;76:1211–6.
  4. Hesse S, Oehlwein C, Barthel H, et al. Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 2006;113:1177–90.
  5. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–10.
  6. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175–82.
  7. Ravina B., Eidelberg D., Ahlskog J. E., Albin R. L., Brooks D. J., Carbon M., Dhawan V., Feigin A., Fahn S., Guttman M., Gwinn-Hardy K., McFarland H., Innis R., Katz R. G., Kieburtz K., Kish S. J., Lange N., Langston J. W., Marek K., Morin L., Moy C., Murphy D., Oertel W. H., Oliver G., Palesch Y., Powers W., Seibyl J., Sethi K. D., Shults C. W., Sheehy P., Stoessl A. J., Holloway R., The role of radiotracer imaging in Parkinson disease, 10.1212/01.wnl.0000149403.14458.7f
  8. Dodel RC, Hoffken H, Moller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson’s disease: a decision-analytic approach. Mov Disord 2003;7(18 Suppl):S52–62.
  9. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 1999;28:99–102.
  10. Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res 2002;11:91–115.
  11. Cooper K, Brailsford SC, Davies R, Raftery J. A review of health care models for coronary heart disease interventions. Health Care Manag Sci 2006;9:311–24.
  12. Koch W, Hamann C, Radau PE, Tatsch K. Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging 2007;34:1265–73.
  13. Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson’s disease. In: Watts RL, Koller WC, editors. Movement disorders. New York: McGraw-Hill; 1997. p. 137–52.
  14. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med 1998;39:1500–8.
  15. Van Laere K., De Ceuninck L., Dom R., Van den Eynden J., Vanbilloen H., Cleynhens J., Dupont P., Bormans G., Verbruggen A., Mortelmans L., Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1, 10.1007/s00259-004-1480-6
  16. Acton PD, Newberg A, Plossl K, Mozley PD. Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson’s disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol 2006;51:575–85.
  17. Chou KL, Hurtig HI, Stern MB, et al. Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson’s disease. Parkinsonism Relat Disord 2004;10:375–9.
  18. McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305–13.
  19. Rajput A.H., Rozdilsky B., Rajput Alex, Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study, 10.1017/s0317167100031814
  20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.
  21. Jankovic J. Essential tremor: clinical characteristics. Neurology 2000;54:S21–5.
  22. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484–91.
  23. Beyer MK, Herlofson K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 2001;103:7–11.